Atara Biotherapeutics Inc - Company Profile

All the sales intelligence you need on Atara Biotherapeutics Inc in one solution.

Save hours of research time with a comprehensive
Sales Intelligence Solution.
Understand how Atara Biotherapeutics Inc fits into your total
addressable market and Ideal Customer Profile.
Gain competitive edge with triggers that tell you
when and how to engage with Atara Biotherapeutics Inc.

Atara Biotherapeutics Inc: Premium Databases

Contact the team or request a demo to find out how our data can drive your business forward

Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.

Headline	Published	Journalists
Showing 2 of 2 results.
Deserunt mollit sunt Lorem laborum do id aliqua dolore	14 Jul 2020	Lorem
Atara’s Phase III tab-cel for EBV+PTLD has experts keen on 68% or higher ORR benchmark for off-label front-line use instead of Roche/Biogen’s approved Rituxan	14 Jul 2020	Ayisha Sharma;Bernarda Tundzhay
KPCB China fund seeks US, EU and Japanese in-licensing deals to incubate domestic companies – exec	03 Apr 2014	Natalie Morrison

Delivers exclusive investigative journalist content including breaking news and analysis ahead of market-moving events.

Drug Insights:

Forward-looking, nuanced, qualitative asset analysis on development, approval & market/reimbursement potential
Material intelligence on competitors, including breaking news
Insight on companies’ business development needs and strategies

Outsourcing Insights:

Insight on companies’ CRO and business development needs, strategies and relationships

Remove risk and uncertainty

Gain a competitive edge

Secure actionable leads

Gain a 360-degree view of Atara Biotherapeutics Inc and make more informed decisions for your business

Still looking?

Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.

Explorer

Access more premium companies when you subscribe to Explorer